# A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

> **NCT00460850** · PHASE4 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 60 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a (40KD) [PEGASYS]

## Key facts

- **NCT ID:** NCT00460850
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Low recruitment rate due to treatment regimen change
- **Last updated:** 2008-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460850, "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00460850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*